Blue Earth Team

Our Board of Directors come from a wide-range of relevant backgrounds and make an active contribution to company strategy.

Board Members

  • Iraj Ali's photo
    Iraj Ali

    Board Member

    Iraj is a Partner of Syncona LLP. Previously, he was an Associate-Principal at McKinsey & Company where he specialised in product launch. He has been involved in several major pharmaceutical launches across developed and emerging markets and was a co-founder of McKinsey’s US launch practice and leader of speciality launch in Europe. Prior to joining McKinsey he held roles in scientific research: EMBO Research Scholar (UCSC), Drug Discovery Scientist (RiboTargets, Cambridge). Iraj has a PhD in Biochemistry from Cambridge University.

  • Jonathan Allis's photo
    Jonathan Allis

    Chief Executive Officer

    Jonathan Allis is the founding CEO of Blue Earth Diagnostics. Prior to this role, Jonathan was the General Manager for PET at GE Healthcare Life Sciences, and had global responsibility for GE Healthcare’s PET agent and PET synthesis platforms business. He has previously held positions in R&D, Marketing and Product Development at GE Healthcare, Amersham plc, Siemens Medical Solutions and Oxford Magnet Technology, in the UK, USA and Germany.

    Jonathan is co-chair of the Society of Nuclear Medicine and Molecular Imaging Value Initiative Industry Alliance for 2017 – 2018.

    Jonathan has an undergraduate degree in Physics from the University of Cape Town and a doctorate in Biochemistry from the University of Oxford.

  • Martin Murphy's photo
    Martin Murphy


    Martin is the Chief Executive Officer of Syncona Partners LLP.  Previously, he was a Partner at MVM Life Science Partners LLP, a leading venture capital company focused on life science and healthcare investments. During his time at MVM, Martin was a member of the Management and Investment Committees and led MVM’s European operations.  He was involved in a number of successful investments including PregLem SA (sold to Gedeon Richter), Momenta Pharmaceuticals, Inc, (NASDAQ:  MNTA), Healthcare Brands International (sold to Meda AB) and Heptares Therapeutics Ltd. Before MVM, Martin had roles with 3i Group plc and McKinsey & Company. Martin has a PhD in Biochemistry from Cambridge University.